CorMedix Inc.

CorMedix Inc.
Stock Exchange NYSE
EPS
$1.18
Market Cap
$218.85 M
Shares Outstanding
23.8 M
Public Float
102.13 M
CorMedix Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
81.9 M
Public Float
78.13 M

Profile

Address
400 Connell Drive
Berkeley Heights New Jersey 07921
United States
Employees -
Website http://www.cormedix.com
Updated 07/08/2019
CorMedix, Inc. operates as a pharmaceutical and medical device company that seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E.

Financials

View All
Created with Highcharts 5.0.14CorMedix Inc.Net Income. Fiscal year is January-December. All values USD Thousands.9 1339 13320 45320 45318 18718 18724 64324 64333 00933 00926 82926 829201320142015201620172018010k20k30k40k
Created with Highcharts 5.0.14CorMedix Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.221891892102102242243293294294292013201420152016201720180100200300400500

Myron Kaplan
Chairman
Mohammed Khoso Baluch
Chief Executive Officer & Director